Arul M. Chinnaiyan, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, was awarded the 2022 Sjöberg Prize by the Royal Swedish Academy of Sciences.
The phase III ARANOTE trial, investigating Nubeqa (darolutamide) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, has met its primary endpoint of radiological progression-free survival. Nubeqa plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT.
